Skip to main content

Table 3 Univariate and multivariate analyses for overall survival of the entire cohort

From: The role of muscle depletion and visceral adiposity in HCC patients aged 65 and over undergoing TACE

  Univariate analysis Multivariate analysis
  HR (95% CI) P value HR (95% CI) P value
Age (year) 1.060 (1.030–1.090) < 0.001 1.057 (0.946–1.024) < 0.001
Sex 0.982 (0.726–1.330) 0.905   
BMI (kg/m2) 0.983 (0.942–1.030) 0.446   
Diabetes 1.170 (0.871–1.570) 0.295   
Hypertension 0.759 (0.573–1.010) 0.056   
Cardiovascular attack 1.330 (0.703–2.510) 0.381   
Other malignancy 1.400 (0.810–2.410) 0.229   
Renal failure on dialysis 1.920 (0.984–3.760) 0.056   
Alcohol 0.937 (0.711–1.240) 0.645   
Smoking 0.922 (0.700–1.220) 0.565   
Etiology   0.002   
 Hepatitis B 1   
 Hepatitis C 1.802 (1.295–2.507) < 0.001   
 Others 1.314 (0.917–1.883) 0.137   
Variceal bleeding 1.760 (0.437–7.110) 0.426   
Ascites 1.910 (1.060–3.440) 0.030   
MELD score 1.100 (1.050–1.160) < 0.001 1.078 (0.928–1.009) 0.027
Number of tumors 1.250 (0.947–1.650) 0.116   
Size of tumor (cm) 1.060 (1.020–1.110) 0.006 1.083 (0.923–1.026) 0.004
Albumin (g/dL) 0.467 (0.358–0.611) < 0.001 0.523 (1.912–0.383) < 0.001
Platelet (uL) 0.996 (0.993–0.999) 0.004 0.996 (1.004–0.993) 0.006
BCLC   0.022   0.015
 stage 0 1 1
 stage A 1.691 (1.012–2.824) 0.045 1.711 (0.585–1.012) 0.045
 stage B 2.062 (1.221–3.480) 0.007 2.003 (0.499–1.148) 0.014
Infiltrative type of HCC 1.210 (0.300–4.870) 0.791   
Serum AFP (ng/mL) 1.000 (1.000–1.000) 0.573   
MDVA 1.501 (1.118–2.014) 0.007 1.515 (0.660–1.112) 0.009
Objective tumor response 0.614 (0.448–0.843) 0.003 0.680 (1.471–0.488) 0.023
  1. AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; BMI, body mass index; HCC, hepatocellular carcinoma; MDVA, muscle depletion with visceral adiposity; MELD, model for end-stage liver disease